Longitudinal change in CDC42 in psoriasis: correlation with disease activity and treatment response.

Objective

To investigate longitudinal CDC42 change and its correlation with disease activity and treatment response in patients with psoriasis.

Methods

This prospective study detected serum CDC42 at months (M) 0, M1, M3 and M6 in 150 patients with psoriasis with current initiation of topical therapy/phototherapy/systemic therapy.

Results

CDC42 was positively related to systemic biologic treatment history (p = 0.025) but negatively associated with psoriatic area (p = 0.010) and Psoriasis Area Severity Index (PASI; p < 0.001). CDC42 continuously elevated from M0 to M6 (p < 0.001). CDC42 at M1/M3/M6 was enhanced in patients with current systemic biologic therapy and PASI 75 or 90 response at M6 versus those without (all p < 0.050).

Conclusion

Increased serum CDC42 level reflects reduced disease severity and better treatment response in patients with psoriasis.